Disappointing study results for Ligand and Amgen

Ligand Pharmaceuticals Inc. (Nasdaq: LGND) partner Amgen Inc. (Nasdaq: AMGN) reported disappointing results from a Phase 3 trial of Kyprolis. Shares of Ligand Pharmaceuticals plummeted $13.45 to close at $99.64 while Amgen stock dropped $1.90 to close at $171.63.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.